Haemonetics Corp. (HAE) intrinsic value & 10-year financials
Haemonetics Corp. (HAE) has a Graham intrinsic value of $43.33 per share. At $118.28 on Oct 17, 2026, the stock trades 173% above that value. Over the last 10 fiscal years revenue grew 4.7% a year to $1.3B, with an average return on invested capital of 6.8%.
- Graham intrinsic value
- $43.33
- Share price (Oct 17, 2026)
- $118.28
- Price vs Graham value
- 173% above
- Market cap
- $5.6B
- Revenue (FY2026)
- $1.3B
- Revenue growth (10-yr CAGR)
- 4.7%
- ROIC (10-yr avg)
- 6.8%
- Free cash flow (FY2026)
- $260.4M
HAE 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2026 | $1.3B | $97.3M | $2.05 | $260.4M | 11.7% | 6.6% |
| FY2025 | $1.4B | $167.7M | $3.31 | $142.4M | 16.3% | 10.2% |
| FY2024 | $1.3B | $117.6M | $2.29 | $115.5M | 12.6% | 8.5% |
| FY2023 | $1.2B | $115.4M | $2.24 | $162.9M | 13.4% | 9.5% |
| FY2022 | $993.2M | $43.4M | $0.84 | $75.8M | 8.1% | 4.2% |
| FY2021 | $870.5M | $79.5M | $1.55 | $71.8M | 10.3% | 8.2% |
| FY2020 | $988.5M | $76.5M | $1.48 | $109.5M | 10.5% | 10.5% |
| FY2019 | $967.6M | $55.0M | $1.04 | $40.3M | 8.6% | 7.5% |
| FY2018 | $903.9M | $45.6M | $0.85 | $145.6M | 6.2% | 4.9% |
| FY2017 | $886.1M | -$26.3M | -$0.51 | $83.6M | -2.2% | -2.0% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
HAEMONETICS CORP has demonstrated mature, steady growth, with revenue compounding at 4.7% annually over the past decade.
HAEMONETICS CORP has historically struggled to out-earn its cost of capital, averaging just 6.8% ROIC.
Over the decade, HAEMONETICS CORP shows that the company has leveraged its balance sheet to sustain operations.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, HAEMONETICS CORP is modeled at 8.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $43.33 per share.